From Our Partners
Saturday, June 25, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

BMC Awarded 21M to Investigate Tuberculosis Biomarkers

by Global Biodefense Staff
November 14, 2014
TB - Mycobacterium tuberculosis

Boston Medical Center (BMC) has been awarded a grant from the National Institutes of Health (NIH) to investigate why Mycobacterium tuberculosis infection (MTB) affects individuals so differently.

The grant, worth up to $21 million over seven years, will allow researchers at BMC, Boston University School of Medicine (BUSM) and Boston University School of Public Health (BUSPH), to identify biomarkers that indicate whether a person infected with the bacteria that causes tuberculosis (TB) is likely to develop symptoms of the disease in their lifetime or will be cured by treatment.

The ultimate goal of this research is to develop new tools for more effective prevention and treatment of TB.

One third of the world’s population is currently infected with MTB. According to the World Health Organization, approximately 9 million individuals globally became ill from TB, and 1.5 million of those individuals died, in 2013. TB is spread person to person through the air and most often affects young people or those with compromised immune systems. Many people who contract TB will never develop symptoms, which include a cough, fever, night sweats and weight loss.

While there are treatments available, they can take up to six months to completely kill the bacteria. Treatment failure happens frequently as people discontinue treatment once symptoms disappear without finishing their entire prescribed dose. However, because the bacteria are not all killed, patients relapse and then need more treatment, which can eventually lead to drug resistance and even death for some individuals.

“There have been strides in reducing TB mortality rates worldwide, but it remains one of the most deadly diseases and disproportionately affects women and individuals in low and middle-income countries,” said Jerrold Ellner, MD, chief of infectious diseases at BMC and professor of medicine at Boston University School of Medicine (BUSM) who will serve as the study’s principal investigator. “Integrating cutting-edge translational approaches in both human and experimental models will help us identify the biomarkers of TB infection and disease and ultimately help us target interventions to prevent TB and develop a shorter-course treatment regimen, which are fundamental to ending the disease.”

Ellner and colleagues proposed to test high-risk cohorts of households with active cases of TB and the TB cases themselves in South Korea and Brazil – two areas with high rates of TB – in order to determine risk factors for progression to active TB after infection, and early markers of bacteria being eradicated in response to chemotherapy. They also will investigate if some individuals have an immunity to TB that enables them to remain asymptomatic.

“We are hopeful that this study will generate ground breaking results that, in the long term, could significantly reduce the number of individuals worldwide who develop TB and lead to lower mortality rates from this infectious disease,” said Ellner.

Source: Boston University Medical Center, adapted.

From Our Partners
Tags: AwardsBiomarkersTuberculosis

Related Posts

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Pathogens

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Supplemental Funding for Research at NIAID Regional Biocontainment Laboratories
Biosecurity

Supplemental Funding for Research at NIAID Regional Biocontainment Laboratories

May 5, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC